

A2780 | 300491

Description	A2780	1972			A2780
	A2780			TP53 BRCA1	
	A2780				
	A2780	VEGF	-2		A2780
	A2780		PARP		
	A2780			A2780	

Organism

Tissue

Metastatic site Primary tumor site (ovary)

Applications Ovarian cancer research; cisplatin sensitivity baseline model; PARP inhibitor evaluation; DNA damage response; platinum-based chemotherapy studies; xenograft models

Synonyms A-2780 2780 A2780S

Age

Gender

Morphology Epithelial-like

Cell type Epithelial cells

Growth properties

Citation A2780 Cytion 300491

A2780 | 300491

Biosafety level	1
NCBI_TaxID	9606
CellosaurusAccession	CVCL_0134
GMO Status	No genetic modification; wildtype ovarian endometrioid carcinoma; parental line for A2780/DDP cisplatin-resistant derivative
Culture Medium	RPMI 1640 w 2.0 mM w 2.0 g/L NaHCO3 Cytion 820700a
Supplements	10% FBS
Dissociation Reagent	Accutase
Subculturing	15 PBS T25 3-5 T75 5-10 Accutase T25 1-2 T75 2.5
Split ratio	1 to 5
Seeding density	1 to 3 × 10 ⁴ cells/cm ²
Fluid renewal	2 3
Freeze medium	FBS +10% DMSO CM-1 Cytion 800100 CM-1 Cytion 800100

A2780 | 300491

Thawing and Culturing Cells				
1.				
2.		-150°C		3
3.		37°C	40-60	
4.			70%	
5.		8	15	
6.	300 x g	3		
7.	10		T25	T25
8.				

Incubation Atmosphere 37°C, 5% CO₂

Flask Coating

Freezing Procedure -78 °C

Shipping Conditions -78 °C

Storage Conditions -150 -196 -80 °C

/ /HLA

Sterility PCR